Skip to content

Sodium nitrite radio biological properties as a radio sensitizer

Radiologic Response to Conventional Whole Brain Radiation Therapy plus Concurrent Intravenous Infusion of Sodium Nitrite versus Radiation Therapy Alone In Patients with Brain Metastases

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013101515026N1
Enrollment
70
Registered
2013-10-25
Start date
2013-10-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain metastasis. Secondary malignant neoplasm of brain and cerebral meninges

Interventions

Intervention 1: Whole brain radiation therapy, both arms of the trial, parallel opposed 6MV photon beams, total dose 30 Gy in 10 fractions, 5 days a week, for 2 weeks. Intervention 2: Sodium nitrite,
Treatment - Other
Treatment - Drugs
Whole brain radiation therapy, both arms of the trial, parallel opposed 6MV photon beams, total dose 30 Gy in 10 fractions, 5 days a week, for 2 weeks
Sodium nitrite, 2 hour intravenous infusion, 267 microgram per kilogram per hour of 3% solution diluted in half liter of normal saline before each fraction of radiation

Sponsors

Ahvaz Jundishapur University of Medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Histopathologically confirmed extra cranial malignancy. 2. At least one brain metastasis >= 1 cm in size demonstrated on a gadolinium enhanced T1 sequence MRI scan.3. Patients must have an estimated survival of at least 4 weeks. 4. ECOG performance status of 0-3. Exclusion criteria: 1. Major medical illnesses or psychiatric impairments which, in the investigator's opinion, will prevent completion of the protocol therapy.2. Previous radiotherapy to the head. 3. Patients who cannot be regularly followed. 4. Leptomeningeal involvement

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Radiologic response. Timepoint: One month after completion of intervention. Method of measurement: According to response evaluation criteria in solid tumors version 1.1 (RECIST).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Bagheri

Ahvaz Jundishapur University of Medical sciences

alibagheri.md@gmail.com+98 61 1374 0236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026